超声乳化联合两枚iStent inject±内路睫状体光凝的疗效
这项回顾性纵向研究比较了超声乳化联合两枚iStent植入联合或不联合内路睫状体光凝(ECP)治疗高眼压或早中期开角型青光眼的12个月结果。联合ECP组(ICE2)63眼、单纯Phaco-iStent组46眼,ICE2组基线眼压更高、平均偏差更低。12个月时ICE2组眼压降幅35%显著优于21%,最终眼压和用药数均更低,视力与安全性相当。
要点
- ICE2组12个月眼压降幅35%,显著优于单纯Phaco-iStent组的21%。
- ICE2组最终眼压13.05±2.18 mmHg,低于对照组的14.09±1.86 mmHg。
- 两组最终用药数ICE2组1.24±1.05 vs 1.39±1.03,视力与安全性相当。
核心结论
- 在12个月随访中,ICE2术式在眼压和用药数量降低方面优于单纯超声乳化联合iStent植入。
研究设计与样本
- 纵向回顾性12个月研究,纳入高眼压或早中期开角型青光眼患眼。
- ICE2组63眼,Phaco-iStent组46眼。
- 术前评估疾病程度、眼压和青光眼药物耐受性后制定手术方案。
- 在基线、术后1周、5周、3个月、6个月、12个月评估最佳矫正视力(BCVA-logMAR)、眼压(mmHg)和用药数量。
主要发现
- ICE2组基线眼压19.97±4.31 mmHg高于Phaco-iStent组17.63±3.86 mmHg(p=0.004)。
- ICE2组基线平均偏差-7.20±2.58 dB低于Phaco-iStent组-4.94±4.51 dB(p=0.037)。
- 基线用药数量两组相当:ICE2组2.22±1.06 vs Phaco-iStent组2.07±1.02(p=0.442)。
- 术后12个月眼压较基线降幅ICE2组35% vs Phaco-iStent组21%(p=0.03)。
- 两组眼压较基线绝对降幅均显著(p<0.001),最终眼压ICE2组13.05±2.18 mmHg低于Phaco-iStent组14.09±1.86 mmHg(p=0.01)。
关键数值与推荐
- 主要结局为12个月时眼压较用药基线下降的百分比。
- 次要结局包括眼压/用药绝对降幅、BCVA和术后并发症。
- 12个月用药数量ICE2组1.24±1.05 vs Phaco-iStent组1.39±1.03(p=0.01)。
- 最终BCVA Phaco-iStent组0.11±0.18 vs ICE2组0.08±0.08(p=0.309)。
- 安全性结局两组相当。
临床怎么用
- 对于高眼压或早中期开角型青光眼需白内障手术者,可考虑超声乳化联合两枚iStent植入并加用ECP以进一步降低眼压和减少用药。
局限性
- 本研究为回顾性纵向研究,非随机对照,两组基线眼压和平均偏差存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Comparing outcomes after combined phacoemulsification, two iStents insertion and endocyclophotocoagulation (ECP) versus phacoemulsification-iStents alone. METHODS: This is a longitudinal retrospective 12 months study in eyes with ocular hypertension or early-to-moderate open angle glaucoma. Level of disease, intraocular pressure (IOP) and tolerance of glaucoma medication were considered before planning surgery. Best-corrected visual acuity (BCVA-logMAR), IOP (mm Hg), number of medications were assessed at baseline, week 1, week 5, month 3, 6, 12 postop. MAIN OUTCOME: percentage (%) in IOP reduction at 12 months vs medicated baseline. SECONDARY OUTCOMES: absolute values of IOP/medication reduction, BCVA and postop complications. RESULTS: The ICE2 (two iStents-cataract extraction-ECP) group included 63 eyes and Phaco-iStent group included 46 eyes. Baseline IOP was higher in the ICE2 than phaco-iStent group (19.97±4.31 mm Hg vs 17.63±3.86 mm Hg, p=0.004) and mean deviation was lower (-7.20±2.58 dB vs -4.94±4.51 dB, p=0.037). Number of medications were comparable at baseline: 2.22±1.06 (ICE2) vs 2.07±1.02 (phaco-iStent), p=0.442. At month 12 postop, IOP in the ICE2 group decreased 35% from baseline vs 21% in the phaco-iStent group (p=0.03); absolute IOP reduction was significantly lower than baseline in each group (p<0.001), yet final IOP was lower in the ICE2 group than phaco-iStent group (13.05±2.18 mm Hg vs 14.09±1.86 mm Hg, p=0.01). Similar results were found for glaucoma medication (1.24±1.05 in ICE2 group vs 1.39±1.03 in phaco-iStent group, p=0.01). Final BCVA was 0.11±0.18 (phaco-iStent group) vs 0.08±0.08 (ICE2 group), p=0.309. Safety outcomes were comparable between groups. CONCLUSION: ICE2 procedure offers better results in IOP/medication reduction at 12 months than phacoemulsification-iStents alone.
引用
- Pantalon AD, Barata ADO, Georgopoulos M, et al. Outcomes of phacoemulsification combined with two iStent inject trabecular microbypass stents with or without endocyclophotocoagulation. Br J Ophthalmol. 2020. PMID: 31980421. doi:10.1136/bjophthalmol-2019-315434
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。